QQ客服 官方微博 反馈留言

	Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
	Ouyang, Xuenong; Shi, Meiqi; Jie, Fangwei; Bai, Yuxian; Shen, Peng; Yu, Zhuang; Wang, Xiuwen; Huang, Cheng; Tao, Min; Wang, Zhehai
刊名	INVESTIGATIONAL NEW DRUGS
	2018
卷号	36期号:2
关键词	Phase III Dulanermin NSCLC Progression-free survival Objective response rate
ISSN号	0167-6997
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3605059
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Ouyang, Xuenong,Shi, Meiqi,Jie, Fangwei,et al. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer[J]. INVESTIGATIONAL NEW DRUGS,2018,36(2).
APA	Ouyang, Xuenong.,Shi, Meiqi.,Jie, Fangwei.,Bai, Yuxian.,Shen, Peng.,...&Feng, Jifeng.(2018).Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.INVESTIGATIONAL NEW DRUGS,36(2).
MLA	Ouyang, Xuenong,et al."Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer".INVESTIGATIONAL NEW DRUGS 36.2(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。